Αποτελέσματα Αναζήτησης
2 ημέρες πριν · In the US, high prescription drug costs are a major barrier to the optimal treatment of many health conditions. About 3 in 10 adults struggle to afford their medicines, and rates are even higher among patients with multiple chronic conditions, those with low socioeconomic status, and those who identify as Black or Latino. 1,2 Notably, cost-related medication nonadherence is associated with ...
4 Αυγ 2022 · Legislation remains a critical potential tool in reducing drug prices and costs, and the HHS plan released last fall highlights priorities such as drug price negotiation in Medicare, caps on out-of-pocket costs, and policies to slow price increases over time on existing drugs.
23 Ιουν 2020 · Global spending on prescription drugs in 2020 is expected to be ~$1.3 trillion; the United States alone will spend ~$350 billion 1. These high spending rates are expected to increase at a rate of...
10 Φεβ 2021 · These legislations can curb drug costs and thus potentially improve affordability as well as access to medicines, improve patient adherence to their medications, and consequently, treatment outcomes. However, other arguments warn against far-reaching unintended negative consequences.
In naming drugs, the most important considerations are avoiding drug names that are too similar to existing names—and therefore might compromise patient safety—and making sure the drug name communicates accurate information about the action or use of the substance.
21 Φεβ 2020 · To bring down the high prices of drugs in the United States, Congress should not just focus on regulating prices themselves; it should reform the whole system that governs competition and...
18 Ιαν 2024 · The Inflation Reduction Act of 2022 allows the US government to negotiate drug prices for Medicare, which is expected to lower drug costs. The first 10 price-protected drugs — including the blood thinner apixaban (Eliquis) and the diabetes medicine sitagliptin (Januvia) — take effect in 2026.
